Virtuix Coverage Initiated with Buy Rating, $9 Target and 165% Upside
VTIX•Emerging Growth Research initiated coverage on Virtuix Holdings with a Buy-Emerging rating and $9.00 price target, implying 165% upside from its $3.40 share price. The report cites 25 patents, 3,000-unit/month production, Meta distribution partnership, U.S. defense contracts, and projected 20% fiscal 2027 and 300% fiscal 2028 revenue growth.
1. Coverage Initiation and Price Target
Virtuix received a Buy-Emerging initiation with a 12-month price target of $9.00 per share, implying roughly 165% upside from its recent $3.40 closing price.
2. Consumer VR Platform Expansion
Virtuix’s Omni One omni-directional treadmill holds 25 granted patents (five pending) and a 3,000-unit-per-month production capacity, supported by a new distribution partnership targeting six million Meta Quest headset users.
3. Defense Contracts and M&A Strategy
Virtuix has secured SBIR Phase 1 funding and initial contracts from the U.S. Air Force, Marine Corps and Navy, with additional sales to West Point and other academies; defense gross margins are estimated at 60–70%, and management is pursuing strategic defense acquisitions.
4. Revenue Outlook and Financial Position
Revenue grew 41% year-over-year over the nine months to December 2025, with consumer sales up 60% versus prior-year levels; fiscal 2027 revenue is projected to increase ~20%, followed by ~300% in fiscal 2028, and the company holds $9.5 million in cash, funding operations through 2026.
